Ads
related to: varicose vein patient information leaflet fda
Search results
Results from the WOW.Com Content Network
The FDA has approved polidocanol injections for the treatment of small varicose (less than 1 mm in diameter) and reticular veins (1 to 3 mm in diameter). Polidocanol works by damaging the cell lining of blood vessels , causing them to close and eventually be replaced by other types of tissue.
CHIVA method is a type of surgery used to treat varicose veins that occur as a result of long term venous insufficiency. [1] The term is a French acronym for Conservatrice Hémodynamique de l'Insuffisance Veineuse en Ambulatoire (ambulatory conservative hemodynamic treatment venous insufficiency).
Calcium dobesilate is a vasoprotective.It is the calcium salt of dobesilic acid.It is a synthetic molecule with the ability to reduce capillary permeability in the body. In Switzerland the drug is sold by the pharmaceutical company OM Pharma under the trade name of Doxium in capsules containing 500 mg of active ingredient.
Each country or region has their own regulatory body. In the European Union, the European Medicines Agency has jurisdiction and the relevant documents are called the "summary of product characteristics" (SPC or SmPC) and the document for end-users is called the "patient information leaflet" or "package leaflet".
Varicose veins are unlikely to be caused by crossing the legs or ankles. [17] Less commonly, but not exceptionally, varicose veins can be due to other causes, such as post-phlebitic obstruction or incontinence, venous and arteriovenous malformations. [18] Venous reflux is a significant cause. Research has also shown the importance of pelvic ...
Sclerotherapy has been used in the treatment of spider veins and occasionally varicose veins for over 150 years. Like varicose vein surgery, sclerotherapy techniques have evolved during that time. Modern techniques including ultrasonographic guidance and foam sclerotherapy are the latest developments in this evolution.
Ads
related to: varicose vein patient information leaflet fda